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Abstract
Background: Generalized tonic-clonic seizures (GTCSs) are the main risk factor for sudden unexpected death in
epilepsy (SUDEP). Experimental and clinical data strongly suggest that the majority of SUDEP results from a postictal
respiratory dysfunction progressing to terminal apnea. Postictal apnea could partly derive from a seizure-induced
massive release of endogenous opioids. The main objective of this study is to evaluate the efficacy of an opioid
antagonist, naloxone, administered in the immediate aftermath of a GTCS, in reducing the severity of the postictal
central respiratory dysfunction.
Methods/design: The Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients with
Epilepsy (ENALEPSY) study is a multicenter, double-blind, randomized, placebo-controlled trial conducted in
patients with drug-resistant focal epilepsy who are undergoing long-term video-electroencephalogram (EEG)
monitoring (LTM) in an epilepsy monitoring unit (EMU). We plan to randomize 166 patients (1:1) to receive
intravenous naloxone (0.4 mg) or placebo in the immediate aftermath of a GTCS. Because inclusion in the
study needs to take place prior to the occurrence of the GTCS, and because such occurrence is observed in
about one-fourth of patients undergoing LTM, we plan to include a maximum of 700 patients upon admission in the
EMU. The primary endpoint will be the proportion of patients whose oxygen saturation is <90 % between 1 and
3 min after the end of a GTCS. Secondary outcomes will include the following: the proportion of patients who
show postictal apnea, the occurrence and duration of postictal generalized EEG suppression, the total duration of
the postictal coma, postictal pain, and the number of patients who have a second GTCS within 120 min after the
intravenous injection.
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Discussion: The demonstration of naloxone’s efficacy on the severity of postictal hypoxemia will have two
primary consequences. First, naloxone would be the first and only therapeutic approach that could be delivered
immediately to reverse postictal apnea. Second, demonstration that an opioid antagonist can effectively reduce
postictal apnea would pave the way for an assessment of a preventive therapy for SUDEP targeting the same
pathophysiological pathway using oral administration of naltrexone.
Trial registration: ClinicalTrials.gov identifier: NCT02332447. Registered on 5 January 2015.
Keywords: Epilepsy, SUDEP, Opioids, Naloxone
Background
Sudden unexpected death in epilepsy (SUDEP) is defined
as sudden, unexpected, witnessed or unwitnessed, non-
traumatic, and nondrowning death in patients with epi-
lepsy, with or without evidence of a seizure and excluding
documented status epilepticus, in which postmortem
examination does not reveal a toxicologic or anatomic
cause of death [1]. SUDEP primarily affects young adults
with drug-resistant epilepsy, with an incidence of about
0.4 %/year [2]. Among the SUDEP risk factors that have
been individualized so far [2], the presence and frequency
of generalized tonic-clonic seizures (GTCSs), either pri-
mary or secondary generalized), were found to represent
the main ones, with an OR >15 for patients with three or
more GTCSs per month [3].
There is currently no effective treatment to prevent
SUDEP, apart from optimizing antiepileptic drugs
(AEDs) [2, 4]. As underscored by the World Health
Organization, there is an urgent need to develop specific
therapeutic approaches to tackle this issue [5]. Consider-
ing that patients with the highest risk of SUDEP are
young adults who have drug-resistant epilepsy with fre-
quent GTCSs, it has been suggested that research on
SUDEP prevention should be focused on this specific
population [3, 6].
Although the exact pathophysiologic mechanisms that
lead to SUDEP remain unknown [2, 7], most of the evi-
dence lends support to the predominant role of central
respiratory dysfunction [8]. Experimental and clinical
data strongly suggest that most SUDEP results from a
postictal respiratory dysfunction progressing to terminal
apnea, followed by cardiac arrest [8, 9]. In addition, postic-
tal generalized electroencephalogram (EEG) suppression
(PGES), which is another factor associated with SUDEP
[10], might primarily represent an ancillary marker of pro-
found postictal hypoxemia [11]. Importantly, the central
respiratory dysfunction that leads to SUDEP typically oc-
curs between 1 and 3 min after the end of a GTCS [9],
supporting the view that central respiratory dysfunction
might be at least partly triggered by the release of neuro-
transmitter involved in seizure termination [8]. In this
context, there might be a short time window during which
this mechanism might be reversed by an appropriate treat-
ment [8].
Animal studies suggest that seizure-related release of
endogenous opioid peptides participate in termination of
seizures [12]. In patients with epilepsy, functional imaging
studies have confirmed that seizures induce release of en-
dogenous opioids [13, 14]. The brainstem respiratory cen-
ters contain the highest density in opioid receptors [15],
accounting for respiratory depression being one of the
cardinal symptoms of opioid overdose [16, 17].
Our hypothesis is that SUDEP results partly from
postictal apnea promoted by a GTCS-induced massive
release of endogenous opioids, and that an opioid antag-
onist could represent an effective preventive treatment
for SUDEP [8]. This could be achieved by chronic ad-
ministration of naltrexone, an opioid antagonist that has
been used in a large population of patients with chronic
alcoholism at high risk of seizures, without showing any
proconvulsive effect. This is a crucial feasibility issue be-
cause antagonizing a mechanism thought to participate in
seizure termination could theoretically aggravate seizures.
Before evaluating the efficacy of chronic administra-
tion of naltrexone, it is legitimate to perform a proof-of-
concept study by testing the acute effect of an equivalent
injection treatment (naloxone) in the immediate after-
math of GTCS recorded in the hospital during video-
EEG monitoring of patients with refractory epilepsy.
One-third of these patients develop postictal respiratory
dysfunction and hypoxemia [18], which should be re-
duced by our intervention if our hypothesis is correct.
Methods/design
The Efficacy of Naloxone in Reducing Postictal Central
Respiratory Dysfunction in Patients with Epilepsy (ENA-
LEPSY) study is a multicenter, double-blind, randomized,
placebo-controlled trial (Fig. 1 and Additional file 1:
Standard Protocol Items: Recommendations for Interven-
tional Trials [SPIRIT] checklist). The main objective of
the study is to evaluate the efficacy of 0.4 mg intravenous
naloxone versus placebo administered in the immediate
aftermath of a GTCS in reducing the severity of the
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postictal central respiratory dysfunction occurring 1–3
min after the end of the seizure, as measured by peripheral
oxygen saturation measured by pulse oximetry (SpO2).
Study setting
The study will be conducted with patients who have drug-
resistant focal epilepsy investigated with long-term scalp
video-EEG or video-stereoelectroencephalography (video-
SEEG) in 1 of the 15 participating epilepsy monitoring
units (EMUs) in France (see Additional file 2). The modal-
ities of the video-EEG monitoring and patient manage-
ment will be consistent with current practices and will be
similar across all participating centers, including modal-
ities of invasive recording using SEEG in the ten EMUs
that perform both video-EEG and video-SEEG monitor-
ing. Specifically, all of them undergo systematic recording
of SpO2 coupled with video-EEG. The reliability of the
measurement of SpO2 during seizures has been validated
Adult patient with drug-resistant focal epilepsy undergoing long-term video-EEG or video-SEEG monitoring in
one of the participating centre to record and characterize its seizure.
Continuous supervision by one to two specialized nurses during daytime in all partipating centres, allowing immediate
intervention in case of occurrence of a seizure.
Continuous monitoring of pulse oximetry together with video, EEG, and respiration recordings
Patients equipped with a peripheral venous catheter throughout the video-EEG
Excluded:
- Administration of opioid treatment
during three consecutive days
- Consent withdrawal
No GTCS and/or non supervised
GTCS during the video-EEG or
video-SEEG monitoring
GTCS during the long-term video-EEG or
video-SEEG monitoring while being
supervised by a nurse or a physician
RANDOMIZATION
NALOXONE 0.4 mg
administered intravenously immediately
after the end of the seizure
PLACEBO
administered intravenously immediately
after the end of the seizure
Continuous monitoring during the two hours following the GTCS
- SpO 2,
SpO 2,
EKG, EEG
- Post-ictal apnea
- Duration of the post-ictal coma
- Post-ictal pain
- Occurrence of another GTCS
Centralized analyses of EKG and EEG data
Discussion of the results
INCLUSION
Excluded
- Age < 18 years, pregnant or breastfeeding women.
- Hypersensitivity to naloxone.
- History of severe heart disease (myocardial infarc-
tion, heart failure disorder, arrhythmia, severe
hypertension)
- Ongoing opioïd treatment, including both pure ago-
nists and partial agonists.
- Addiction to opioïds, heroin, or any similar sub-
stance.
- Participation in other drug clinical trial within the
last two months
End of follow-up without
randomization
Fig. 1 Flowchart of the trial. EEG Electroencephalogram, EKG Electrocardiogram, GTCS Generalized tonic-clonic seizure, SEEG Stereoelectroencepha-
lography, SpO2 Peripheral oxygen saturation measured by pulse oximetry
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by two studies in which researchers carried out this type
of monitoring [18, 19].
Study duration
Recruitment into the trial commenced in July 2015 and
is anticipated to be completed in July 2018. The duration
of participation of each patient in the trial will be a max-
imum of 36 days. Long-term video-EEG/video-SEEG
monitoring typically lasts between 7 and 15 days, and
occasionally up to 21 days. However, the total duration
of monitoring will be variable across patients, defined by
clinical parameters, specifically the occurrence of a suffi-
cient number of seizures to allow conclusions to be
drawn about the localization of the seizure onset zone.
For safety reasons, a phone visit will be held 15 days
after the end of the monitoring.
Participants
About 25 % of patients with drug-resistant partial epi-
lepsy who are undergoing long-term video-EEG moni-
toring develop at least one focal secondary generalized
tonic-clonic seizure (sGTCS) [18, 20, 21]. However, these
patients cannot be individualized a priori. Therefore, all
adult patients with drug-resistant epilepsy who will
undergo long-term video-EEG monitoring in one of the
participating centers will be included in the study ac-
cording to the following inclusion criteria:
 Adult patients (≥18 years) with drug-resistant focal
epilepsy
 Patients undergoing long-term video-EEG or video-
SEEG monitoring in one of the participating centers
to record and characterize their seizures
 Patients who provide written informed consent to
participate in the study
 Patients affiliated with the French health care system
Patients fulfilling one or more of the following exclu-
sion criteria will not be eligible for inclusion:
 Children (<18 years)
 Pregnant or breastfeeding women
 Hypersensitivity to naloxone
 History of severe heart disease (i.e., myocardial
infarction, heart failure disorder, arrhythmia severe
hypertension)
 Ongoing opioid treatment, including both pure
agonists and partial agonists
 Addiction to opioids, heroin, or any similar substance
 Participation in another drug clinical trial within the
last 2 months
Patients who have an sGTCS during the long-term
video-EEG or video-SEEG monitoring while being
supervised by a nurse or a physician will be randomized
to receive intravenous naloxone (0.4 mg) or placebo.
As indicated in the exclusion criteria, naloxone will not
be allowed for patients receiving ongoing opioid treat-
ment, including both pure agonists and partial agonists.
Therefore, patients receiving ongoing opioid treatment
will be excluded. However, in the context of presurgical
evaluation, especially for patients who undergo invasive
recording with SEEG, the management of pain might re-
quire temporary administration of an opioid agonist. In
such patients, short-lasting administration of opioid treat-
ment following inclusion will be authorized, except for
extended-release formulations of morphine. However, this
will result in temporary ineligibility for randomization
during the 12 h following the last opioid administration. If
pain management requires administration of opioid treat-
ment during 3 consecutive days, the patient will be ex-
cluded from the study.
Interventions
Naloxone is a specific opioid antagonist without partial
agonist activity. Intravenous administration has been ap-
proved in France since 1977 for the treatment of acute
opioid overdose. In this indication, the recommended
starting dose is 0.4 mg [16]. In acute opiate overdose,
the delay between intravenous injection and awakening
ranges from 30 s to 2 min, and its apparent duration of
action is 20–90 min [16]. No epilepsy-related alert has
been reported for this product. Naloxone administration
will consist of naloxone hydrochloride dihydrate
(0.4 mg/ml) packaged in 1-ml vials that can be intraven-
ously administered to the patient without additional di-
lution. The placebo will be isotonic sodium chloride
with preparation in 1-ml vials.
Blinding and randomization
To avoid any follow-up or measurement bias, the patient,
the supervising nurse, or the physician and the investiga-
tor will not be aware of the nature of the administered
treatment. To respect the blinding and to ensure indistin-
guishability, preparations of both naloxone and placebo
will be centralized by the pharmaceutical department of
Hospices Civils de Lyon. The study drugs will then be dis-
tributed to the pharmacies of other investigator sites and
stored at room temperature. Because of urgent need of
treatment in case of occurrence of GTCS, one or more
study treatments will be stored at room temperature in
each EMU according to the expected number of randomi-
zations at each center
Randomization will be centralized, stratified by center,
and balanced by block of patients. For each study center,
randomization lists will be prepared by the clinical research
unit of Hospices Civils de Lyon. The pharmaceutical
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department of Hospices Civils de Lyon will prepare num-
bered batches according to the randomization lists.
In case of the occurrence of a GTCS, the affected pa-
tient will be randomized in a 1:1 ratio and assigned to
the naloxone group or the placebo group. The batch
number will be registered in the patient’s case report
form. All digital data (video, EEG, respiration, SpO2) will
be centralized and evaluated in blinded fashion with
other data by the coordinator investigator of the study,
who will not be involved in the video-EEG monitoring
of the included patient.
If case of occurrence of a serious adverse event, the
Antipoison and Toxicovigilance Center of Lyon will
proceed to unblinding 24 h/24 h upon request by the
study coordinator, the investigators, or the sponsor. A
detailed written procedure for unblinding will be pro-
vided to all persons involved.
Study conduct
All included patients will benefit from continuous moni-
toring of SpO2 and will be have a peripheral venous
catheter inserted throughout the video-EEG/video-
SEEG. During video-EEG/video-SEEG, patients are con-
tinuously supervised by one or two specialized nurses
during the daytime at all participating centers. This con-
tinuous supervision allows immediate intervention in
case of occurrence of a seizure. In six centers, patients
are supervised by one specialized nurse during the night,
whereas they are not supervised in the other centers.
Given this organization of some EMUs, a GTCS might
occur during a period without supervision. Unsupervised
GTCS will not result in randomization, and the patient
will remain eligible for randomization in case of occur-
rence of another GTCS during the monitoring. Inclusion
in the study will not modify antiepileptic drug with-
drawal, the management of which will remain at the dis-
cretion of each center.
In case of occurrence of a GTCS, patients will be ran-
domized (1:1) into one of two groups: a single dose of
1 ml of either (1) naloxone or (2) placebo will be admin-
istered by the supervising nurse or physician, using dir-
ect intravenous injection. The evolution from a focal
seizure to a GTCS being gradual, and the total duration
of the seizure ranging from 2 to 3 min, the injection will
be prepared during the course of the seizure. Given the
assumptions about the role of endogenous opioid release
in the spontaneous termination of seizures, naloxone
will be administrated immediately after the end of the
GTCS and not before. Specifically, treatment administra-
tion will be performed within the 2 min following the
end of the GTCS.
Immediately after the administration of the treatment,
the supervising nurse or physician will monitor respira-
tory movements to detect absence of chest expansion,
SpO2, heartbeat and blood pressure, recovery of con-
sciousness and pain, using a visual analogue scale. In pa-
tients with SpO2 < 85 % during >2 min after the
injection of the study drug, O2 will be administered
using a high-concentration breathing mask (15 L/min).
Occurrence of one or more GTCSs during the 2 h fol-
lowing treatment administration will be monitored.
All digital data (video, EEG, respiration, SpO2) will be
centralized and evaluated blind to other data. An auto-
matic and objective analysis of SpO2 data will be per-
formed using a specific detection algorithm that allows
automatic detection and quantification of SpO2 and
electrocardiogram variations.
Outcome measures
Primary endpoint
The primary endpoint is the proportion of patients
whose SpO2 is <90 % during at least 5 s between 30 s
and 5 min after the onset of intravenous injection of the
study drug in the immediate aftermath of a GTCS. The
delay between the end of the seizure and administration
of the treatment will be precisely determined by the
video recording of the event, given that the nurse or
physician who will administer the study drug will be re-
quired to both loudly order “injection” and raise an arm
at the onset of injection. Previous studies have shown
that the measurement of SpO2 is reliable in the vast ma-
jority of seizures, including GTCSs [18, 19]. To eliminate
artefactual changes of SpO2, however, the criterion of
hypoxemia duration of at least 5 s is required.
Secondary endpoints
Efficacy endpoints
 Number of patients who show postictal apnea,
defined as the absence of chest expansion during a
period >10 s between 1 and 3 min after the end of
the GTCS
 Number of patients for whom O2 administration is
required within the 10 min following the end of a
GTCS
 Number of patients for whom cardiorespiratory
rescue procedure is required within the 10 min
following the end of a GTCS
 Total duration of the postictal generalized EEG
suppression, defined as lack of detectable EEG
activity >10 μV in amplitude on all leads [10]
 Total duration of the postictal coma, defined as the
delay between the end of the seizure and the
recovery of consciousness assessed by the ability to
meet one single verbal command (handshake)
Safety endpoints
 Report of adverse events observed throughout the
study
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 Assessment of pain using a visual analogue scale
immediately after recovery of consciousness
following the postictal coma.
 Number of patients who have a second GTCS
within 120 min after the intravenous injection
Data monitoring
A clinical research assistant mandated by the sponsor will
ensure the successful completion of the study and the col-
lection of data generated by writing, documentation, re-
cording, and report, in accordance with the standard
operating procedures implemented at the Hospices Civils
de Lyon and in accordance with good clinical practice and
regulatory legislation. An independent Data and Safety
Monitoring Board (DSMB) external to the trial investiga-
tors has been established specifically to monitor data
throughout the study to determine if it is appropriate,
from both scientific and ethical standpoints, to continue
the study as planned. The DSMB will meet every year to
review serious adverse events and propose continuing or
stopping the study. The DSMB is made up of three ex-
perts in epilepsy (A. Rossetti, Department of Clinical
Neurosciences, Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland), anesthesiology (Dr. A. Charton,
Strasbourg University Hospital, Strasbourg, France), and
methodology in clinical research (S. Chabaud, Centre
Leon Berard, Lyon, France).
Sample size
Sample size was determined using Fisher’s exact test
with a two-sided alternative hypothesis. For a signifi-
cance level of 5 % (two-tailed), assuming a proportion of
patients whose SpO2 is <90 % during at least 5 s be-
tween 30 s and 5 min after the onset of intravenous in-
jection of the study drug in the immediate aftermath of
a GTCS of 33 % in the control group [18] and 11 % in
the naloxone group, 69 patients should be included in
each group to reject the null hypothesis in 90 % of cases,
with a 95 % CI ranging from 0.077 to 0.547. With a pro-
portion of unusable records for technical reasons of 20
% being expected, 166 patients will be randomized. Be-
cause we anticipate that 25 % of patients eligible for in-
clusion will have a sGTCS during long-term video-EEG
monitoring, we will need to include 700 patients.
Statistical analyses
The primary analysis will be based on the intention-to-
treat principle, including all randomized patients with
usable records for SpO2. The proportion of patients
whose SpO2 is <90 % during at least 5 s between 30 s
and 5 min after the onset of intravenous injection of the
study drug in the immediate aftermath of a GTCS will
be presented in each group (naloxone and placebo) with
the corresponding exact 95 % CI. These proportions will
be compared between the two groups using Pearson’s
chi-square test (or Fisher’s exact test if conditions for
the chi-square test are not fulfilled).
A per-protocol analysis of the primary endpoint will
also be performed in the population, which will com-
prise all randomized patients with usable records for
SpO2 having no major protocol deviation such as pa-
tients in whom the onset of intravenous injection of the
study drug was within the 2 min following the end of
the seizure (whereas those in whom the study drug was
administered >120 s after the end of the seizure will be
excluded). Secondary endpoints will be compared be-
tween groups using Pearson’s chi-square test, Fisher’s
exact test, Student’s t test, or the Wilcoxon-Mann–
Whitney test, depending on the variable studied. The
significance level will be set at 0.05.
Discussion
Although SUDEP is the leading cause of death in people
with chronic refractory epilepsy, there is currently no ef-
fective treatment to prevent SUDEP, apart from optimiz-
ing AEDs [2, 4]. As underscored by the World Health
Organization [5], there is an urgent need to develop spe-
cific therapeutic approaches to tackle this issue. Given
the pathophysiologic link between the occurrence of
central apnea in the aftermath of GTCS and the risk of
SUDEP, treatment strategies aimed at reducing the se-
verity of postictal respiratory dysfunction appear to be
the most promising way to prevent SUDEP [6, 8].
The demonstration of naloxone’s efficacy in reducing
the severity of postictal hypoxemia will have two primary
consequences. First, naloxone would be a therapeutic ap-
proach that could be immediately delivered to reverse
postictal apnea, especially during long-term video-EEG
monitoring. Although rare, SUDEP has occurred during
video-EEG in several EMUs in Europe [9]. In addition, the
availability of employing the intramuscular route for na-
loxone [16] renders possible its use at home, especially for
patients in whom severe postictal hypoxemia would have
been observed in the hospital. By reducing postictal apnea,
naloxone might also shorten the postictal phase and pro-
mote quicker recovery of consciousness.
Second, a demonstration that an opioid antagonist can
effectively reduce postictal apnea would pave the way for
an assessment of a preventive therapy targeting the same
pathophysiologic pathway using naltrexone. Indeed, this
orally administered opioid antagonist can be delivered
over the long term with an excellent safety profile, in-
cluding in patients undergoing alcohol withdrawal at
high risk of seizure, in whom a proconvulsive effect has
not been observed [22, 23]. Following this naloxone
study, the impact of chronic naltrexone therapy might
first be tested for postictal hypoxemia during video-EEG
(by treating patients chronically before and during their
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video-EEG monitoring). If this second study proved
positive, a large-scale study with ambulatory patients
could then be undertaken to test the impact of chronic
naltrexone treatment on the risk of SUDEP in high-risk
populations [8].
Trial status
The study protocol was designed in September 2013 and
funded by the French Ministry of Health in 2014. The
study was registered with ClinicalTrials.gov
(NCT02332447) in January 2015. The first participant
was enrolled on 26 June 2015. A total of 157 patients
have been included so far, of whom 16 have been
randomized.
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